Single Dose of J&J COVID-19 Vaccine Shows Strong Immune Response

Early trial data from Johnson & Johnson’s COVID-19 vaccine candidate AD26.COV2.S has shown that a single dose was enough to generate a strong antibody response.

The company released interim results of a phase 1/2a trial that compared one and two doses of the vaccine vs. a placebo in 1,045 participants. One group consisted of volunteers age 18 to 55 and another group was comprised of adults age 65 to 75.

Almost all participants who received a single dose of the vaccine generated antibodies to the coronavirus after 29 days, the company said.

J&J has begun a phase 3 trial of a single dose of the vaccine vs. a placebo in 60,000 participants across eight countries, the largest late-stage trial of a COVID-19 vaccine to date  (DID, Sept. 24). A single-dose vaccine will have a clear advantage over other vaccine candidates that require two or more doses. — Jordan Williams